CRISPR Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?

CRISPR Therapeutics moved to the commercial stage with its first CRISPR-based approval (CASGEVY commercialization tied to Vertex), but FY2025 revenue was only ~$3.5M (down ~90% YoY) with a ~$581.6M net loss and negative FCF of ~$345.9M. Viking Therapeutics reported no FY2025 revenue, a ~$359.6M net loss, and negative FCF of ~$278.7M, while remaining dependent on its Ligand license and third-party manufacturing. The article frames both as highly speculative, with CRISPR described as more investable than Viking despite high valuation (forward P/E ~19.1 vs Viking ~17.7, sector benchmark 389.1).

Analysis

The market is likely mispricing the difference between a scientific milestone and a scalable business. CRSP has crossed into commercialization, but the equity still behaves like a single-asset, partner-controlled revenue stream; that usually caps multiple expansion until there is evidence of repeatable uptake, not just regulatory success. By contrast, VKTX remains a classic obesity-story premium: the option value is large, but the market is already paying for a future that depends on differentiated efficacy, tolerability, and manufacturing execution in a brutally competitive GLP-1 landscape.

Second-order, VRTX is the cleaner economic beneficiary versus CRSP because it owns the commercialization engine and has the broader balance sheet to absorb slow adoption curves. The most important hidden risk for CRSP is not the headline approval itself, but that the long follow-up tail and IP overhang keep capital trapped while revenue ramps slowly; that tends to compress valuation even when the science is validated. For VKTX, the real vulnerability is supply-chain and partner dependence: if CMO capacity or CMC quality slips, the stock can de-rate before efficacy is even tested by the market.

Contrarian view: the consensus is too focused on “approved” versus “pre-revenue” and not enough on cash burn efficiency and probability-weighted commercialization. CRSP may actually be the lower-risk equity over the next 6-18 months because it at least has a monetization path and a stronger balance sheet, while VKTX is still one data miss away from becoming a financing story. The thesis is falsified if CRSP quarterly revenue inflects materially faster than expected or if VKTX posts a clean, differentiated obesity dataset with credible manufacturing readiness.

Key Decisions for Investors

• Relative-value trade: long VRTX / short CRSP over 3-6 months. Thesis is that commercialization economics accrue more reliably to the partner than to the platform owner; cover the short if CRSP revenue trends improve sequentially for two straight quarters.
• Do not initiate a fresh long VKTX here. Wait for pivotal efficacy + tolerability readout and CMC/manufacturing confirmation; the name is too binary to own without a catalyst window.
• If forced to own one idiosyncratic biotech, prefer a smaller CRSP position over VKTX for 2026. The risk/reward is better balanced by a real product, even if adoption is slow, versus VKTX’s all-or-nothing clinical path.
• Set an alert on CRSP for any material guidance change in milestone revenue or commercial uptake; a downside surprise would be a clean short-entry trigger because the stock’s support is narrative-heavy, not cash-flow-heavy.
• Watch VRTX as the quieter beneficiary of any CRSP commercialization progress. If CASGEVY uptake starts to inflect, VRTX should re-rate faster than CRSP because it owns a larger share of the monetization stack.